TY - JOUR
T1 - Immunotherapy for primary brain tumors
T2 - No longer a matter of privilege
AU - Fecci, Peter E.
AU - Heimberger, Amy B.
AU - Sampson, John H.
N1 - Publisher Copyright:
©2014 AACR.
PY - 2014/11/15
Y1 - 2014/11/15
N2 - Immunotherapy for cancer continues to gain both momentum and legitimacy as a rational mode of therapy and a vital treatment component in the emerging era of personalized medicine. Gliomas, and their most malignant form, glioblastoma, remain as a particularly devastating solid tumor for which standard treatment options proffer only modest efficacy and target specificity. Immunotherapy would seem a wellsuited choice to address such deficiencies given both the modest inherent immunogenicity of gliomas and the strong desire for treatment specificity within the confines of the toxicity-averse normal brain. This review highlights the caveats and challenges to immunotherapy for primary brain tumors, as well as reviewing modalities that are currently used or are undergoing active investigation. Tumor immunosuppressive countermeasures, peculiarities of central nervous system immune access, and opportunities for rational treatment design are discussed.
AB - Immunotherapy for cancer continues to gain both momentum and legitimacy as a rational mode of therapy and a vital treatment component in the emerging era of personalized medicine. Gliomas, and their most malignant form, glioblastoma, remain as a particularly devastating solid tumor for which standard treatment options proffer only modest efficacy and target specificity. Immunotherapy would seem a wellsuited choice to address such deficiencies given both the modest inherent immunogenicity of gliomas and the strong desire for treatment specificity within the confines of the toxicity-averse normal brain. This review highlights the caveats and challenges to immunotherapy for primary brain tumors, as well as reviewing modalities that are currently used or are undergoing active investigation. Tumor immunosuppressive countermeasures, peculiarities of central nervous system immune access, and opportunities for rational treatment design are discussed.
UR - http://www.scopus.com/inward/record.url?scp=84916936048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84916936048&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-0832
DO - 10.1158/1078-0432.CCR-14-0832
M3 - Review article
C2 - 25398845
AN - SCOPUS:84916936048
SN - 1078-0432
VL - 20
SP - 5620
EP - 5629
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 22
ER -